NCT02332668: A Study of Pembrolizumab (MK-3475 in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: MSI-H, PD-L1
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 6 Months to 17 Years (Child
Location of Metastases: 
Additional Notes: 
Exclusions: Patients over the age of 17; Patients with known active central nervous system (CNS) metastases and/or carcinomatous meningitis; Prior therapy with an anti-PD-1, -PD-L1, or PD-L2 agent

Comments are closed.

Up ↑